NCT06912165 A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
| NCT ID | NCT06912165 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Zhejiang Wenda Pharma Technology LTD. |
| Condition | Brief Description of Focus of Study |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2024-12-31 |
| Primary Completion | 2025-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 140 participants in total. It began in 2024-12-31 with a primary completion date of 2025-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Eligibility Criteria
Inclusion Criteria: * Male or female participant aged 18 to 70 years(inclusive)at the time of informed consent. * Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit. ≥10% of BSA involvement at screening visit and randomization; * Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization Exclusion Criteria: * Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.) * Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted * Class III or IV congestive heart failure by New York Heart Association Criteria * Participant with a history of chronic bacterial infections (e.g., chronic pyelonephritis, chronic bronchiectasis, or chronic osteomyelitis).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06912165 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Brief Description of Focus of Study. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06912165 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06912165 currently recruiting?
Yes, NCT06912165 is actively recruiting participants. Contact the research team at qianlu5860@pumcderm.cams.cn for enrollment information.
Where is the NCT06912165 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06912165 clinical trial?
NCT06912165 is sponsored by Zhejiang Wenda Pharma Technology LTD.. The trial plans to enroll 140 participants.